Trump Fast-Tracks Federal Review of Psychedelics, Including Ibogaine
President Trump’s order to speed up psychedelic drug reviews targets medical uses like PTSD treatment for veterans, signaling a notable regulatory shift.
President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate the review and potential approval of certain psychedelic substances, notably including ibogaine. This directive aims to streamline the regulatory and research processes around these drugs, which remain controlled substances largely off-limits for mainstream therapeutic use despite mounting scientific and veteran interest.
Why This Matters
Ibogaine, a naturally occurring psychedelic, has long been discussed as a potential treatment for opioid addiction and other mental health conditions, but it has no current FDA approval and is classified as a Schedule I substance, meaning it is considered to have high abuse potential and no accepted medical use. Trump's order breaks with past federal caution by pushing for faster assessments and potential reclassification or medical authorization pathways. It stands out as an intersection of public health innovation and political recalibration on drug policy.
This effort aligns with growing bipartisan interest—especially among veterans and some conservative lawmakers—in psychedelic therapies to tackle issues like post-traumatic stress disorder (PTSD) and addiction, conditions pervasive among military personnel returning from combat zones. The White House has announced a $50 million federal investment specifically for research into ibogaine, signaling not just regulatory intent but a funding commitment to development and safety evaluation. Health and Human Services Secretary Robert F. Kennedy Jr. has been closely involved in the rollout, highlighting the administration's readiness to modernize drug research frameworks. Notably, FDA Commissioner Dr. Marty Makary suggested faster approval timelines under the new framework, marking a stark shift from the traditionally slow-moving drug approval process 
CNN | 
Washington Post.
This move echoes a broader global trend: countries and states liberalizing access to psychedelics for mental health treatment after decades of prohibition. The U.S. has previously allowed research into psilocybin and MDMA for PTSD and depression under strict controls, but this order potentially fast-tracks operationalizing therapies for wider use. However, ibogaine carries risks — including heart complications — and safety concerns remain high, mandating rigorous oversight.
What to Watch Next
The real test will be in the implementation details: How fast can federal agencies deliver scientifically sound reviews without bypassing critical safety evaluations? Will ibogaine’s reclassification happen quickly, or will it stall amid regulatory caution or political opposition?
Veteran groups and conservative lawmakers supporting this initiative will push for swift outcomes, so expect lobbying and public advocacy to intensify. Watch for FDA announcements on trial approvals and updated drug scheduling over the next 6 to 12 months.
This shift also sets a precedent for how psychedelics might be integrated into U.S. healthcare, potentially reshaping mental health treatment paradigms. If successful, it could unlock billions of dollars in private and public investment and redefine addiction and trauma therapies.
For more on evolving U.S. policies on drug regulation and veterans' health issues, see our 
United States and Global Politics pages.
Stay tuned as this regulatory pivot unfolds. Trump’s order signals a new era where psychedelic science meets political will — and the stakes couldn’t be higher for millions suffering from addiction and PTSD.
Source: Washington Post | CNN
